PAK4 and metabolic dysfunction-associated steatotic liver disease: Therefore, PAK4 inhibition may be a new therapeutic strategy for pathogenic conditions associated with ketogenesis deregulation, such as NAFLD and HCC, owing to its ability to enhance the ketogenic capacities of the liver.